抗肿瘤坏死因子-α单抗及其他生物制剂在克罗恩病中的应用  

Anti-TNF-α monoclonal antibody and novel biological therapy for Crohn's disease

作　　者：李瑾[1] 潘华勤[1] 夏冰[1] 

机构地区：[1]武汉大学中南医院消化内科湖北省肠病医学临床研究中心肠病湖北省重点实验室,武汉430071

出　　处：《中国实用内科杂志》2014年第9期867-870,共4页Chinese Journal of Practical Internal Medicine

基　　金：国家自然科学基金(81070280,81270467)

摘　　要：生物制剂的应用极大地改变了克罗恩病的传统治疗模式。近10余年来,多种新型生物制剂被批准用于常规治疗无效的难治性克罗恩病的治疗,这些生物制剂从最初的抗肿瘤坏死因子-α(TNF-α)单抗发展到后来的抗白细胞黏附分子单抗,显示了基础研究向临床应用的转化以及临床疗效和安全性;但同时一些问题诸如生物制剂失应答、最佳治疗策略、临床治疗的成本-效益比和效益-风险比也逐渐得以关注。Introduction of biological agents for the treatment of Crohn＇s disease （CD） has led to a transformation of the treat- ment paradigm. Through the use of biologics for more than a decade, several novel biological compounds have been approved for application in patients with CD refractory to conventional treatment. These biological agents evolve from the previous anti- TNF-α monoclonal antibodies to recent anti-leukocyte adhesion molecule monoclonal antibodies and display clinical efficacy and safe profile. However, debatable questions are increasingly focused on loss of response, optimal treatment regimens, cost- efficiency and efficiency-risk ratios during biological treatments of CD.

关 键 词：生物制剂 抗TNF-α单抗 克罗恩病 抗白细胞黏附分子单抗 

分 类 号：R574[医药卫生—消化系统]